ISSN: 1175-3277

Journal Home

Journal Guideline

American Journal of Cardiovascular Drugs Q2 Unclaimed

Adis International Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

American Journal of Cardiovascular Drugs is a journal indexed in SJR in Medicine (miscellaneous) and Cardiology and Cardiovascular Medicine with an H index of 60. It has a price of 3190 €. It has an SJR impact factor of 0,79 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,79.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cardiology and Cardiovascular Medicine (Q2) Medicine (miscellaneous) (Q2) Pharmacology (medical) (Q2)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

American Journal of Cardiovascular Drugs

0,79

SJR Impact factor

60

H Index

60

Total Docs (Last Year)

184

Total Docs (3 years)

2987

Total Refs

512

Total Cites (3 years)

174

Citable Docs (3 years)

2.66

Cites/Doc (2 years)

49.78

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

Role of Metabolically Active Drugs in the Management of Ischemic Heart Disease

Aortic Insufficiency

Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience

Reduction of Serum LDL-C Levels

Prevention of Restenosis with Antioxidants

The Sirolimus-Eluting Stent

Clinical Experience with Perindopril in Elderly Hypertensive Patients

The new European Guidelines in Hypertension

Risk of Suicide in Users of Cardiovascular Drugs

Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches

HIV-Related Cardiovascular Disease and Drug Interactions

Could Influenza Vaccination Prevent Myocardial Infarction, Stroke and Sudden Cardiac Death?

SHOW MORE ARTICLES

Modified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris

New strategies for hypertension control

Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol

Photopheresis

Development of Radiocontrast Agents for Vascular Imaging

Pharmacologic Rationale for Trimetazidine in the Treatment of Ischemic Heart Disease

Renal protection

Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists

Medical Management of Chronic Heart Failure in Children

Carnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

Calcium Channel Antagonists in the Treatment of Hypertension